ArticleFrontiers in health services2026
Longitudinal adoption of robotic surgery and changes in prostate cancer care delivery: a 10-year institutional case study.
Article in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-cost medical technologies are usually evaluated by clinical outcomes and cost-effectiveness, while their organizational effects are less often examined. We conducted a 10-year longitudinal institutional case study (2012-2022) of 395 prostate cancer procedures, combining process tracing, descriptive quantitative trends, implementation records, and workflow documentation. Three quantitative indicators were examined across four adoption stages: procedural volume, biopsy-free surgery, and final pathological confirmation. Biopsy-free surgery increased from 13 of 55 procedures (23.6%) during experimentation to 96 of 125 (76.8%) during maturity, and final pathological confirmation increased from 22 of 55 (40.0%) to 96 of 125 (76.8%). Cochran-Armitage tests showed significant increasing trends for both indicators (Z = 6.48 and 5.25, respectively; both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.